Muscular dystrophy: Experimental animal models and therapeutic approaches (Review)

被引:8
作者
Gaina, Gisela [1 ,2 ]
Popa , Alexandra [1 ,3 ]
机构
[1] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Splaiul Independentei 99-101, Bucharest 050096, Romania
[2] Univ Bucharest, Dept Biochem & Mol Biol, Bucharest 050095, Romania
[3] Univ Agron Sci & Vet Med Bucharest, Dept Anim Prod & Publ Hlth, Bucharest 050097, Romania
关键词
muscular dystrophy; animal models; gene therapy; mdx mouse; canine model; pig model; read-through; exon skipping; MDX MOUSE MODEL; GLYCOPROTEIN COMPLEX; MUSCLE FUNCTION; MOLECULAR-BASIS; GENE-THERAPY; DUCHENNE; EXPRESSION; MICE; UTROPHIN; SKELETAL;
D O I
10.3892/etm.2021.10042
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The muscular dystrophies are a heterogeneous group of genetically inherited diseases characterized by muscle weakness and progressive wasting, which can cause premature death in severe forms. Although >30 years have passed since the identification of the first protein involved in a type of muscular dystrophy, there is no effective treatment for these disabling disorders. In the last decade, several novel therapeutic approaches have been developed and investigated as promising therapeutic approaches aimed to ameliorate the dystrophic phenotype either by restoring dystrophin expression or by compensating for dystrophin deficiency. Concurrently, with the development of therapeutic approaches, in addition to naturally occurring animal models, a wide range of genetically engineered animal models has been generated. The use of animals as models of muscular dystrophies has greatly improved the understanding of the pathogenicity of these diseases and has proven useful in gene therapy studies. In this review, we summarize these latest innovative therapeutic approaches to muscular dystrophies and the usefulness of the various most common experimental animal models.
引用
收藏
页数:9
相关论文
共 116 条
  • [1] Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
    Aartsma-Rus, A
    Janson, AAM
    Kaman, WE
    Bremmer-Bout, M
    den Dunnen, JT
    Baas, F
    van Ommen, GJB
    van Deutekom, JCT
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (08) : 907 - 914
  • [2] The use of genetically humanized animal models for personalized medicine approaches
    Aartsma-Rus, Annemieke
    van Putten, Maaike
    [J]. DISEASE MODELS & MECHANISMS, 2020, 13 (02)
  • [3] Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy
    Acharyya, Swarnali
    Villalta, S. Armando
    Bakkar, Nadine
    Bupha-Intr, Tepmanas
    Janssen, Paul M. L.
    Carathers, Micheal
    Li, Zhi-Wei
    Beg, Amer A.
    Ghosh, Sankar
    Sahenk, Zarife
    Weinstein, Michael
    Gardner, Katherine L.
    Rafael-Fortney, Jill A.
    Karin, Michael
    Tidball, James G.
    Baldwin, Albert S.
    Guttridge, Denis C.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (04) : 889 - 901
  • [4] Gene expression and proliferation analysis in young, aged, and osteoarthritic sheep chondrocytes effect of growth factor treatment
    Acosta, Carlos A.
    Izal, Inigo
    Ripalda, Purificacion
    Douglas-Price, Ana Laura
    Forriol, Francisco
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2006, 24 (11) : 2087 - 2094
  • [5] Animal models for muscular dystrophy: valuable tools for the development of therapies
    Allamand, V
    Campbell, KP
    [J]. HUMAN MOLECULAR GENETICS, 2000, 9 (16) : 2459 - 2467
  • [6] In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse
    Aoki, Yoshitsugu
    Nakamura, Akinori
    Yokota, Toshifumi
    Saito, Takashi
    Okazawa, Hitoshi
    Nagata, Tetsuya
    Takeda, Shin'ichi
    [J]. MOLECULAR THERAPY, 2010, 18 (11) : 1995 - 2005
  • [7] Barre-Sinoussi F, 2015, FUTUR SCI OA, V1, DOI [10.4155/FSO.15.63, 10.4155/fso.15.63]
  • [8] Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A
    Bartoli, M
    Roudaut, C
    Martin, S
    Fougerousse, F
    Suel, L
    Poupiot, J
    Gicquel, E
    Noulet, F
    Danos, O
    Richard, I
    [J]. MOLECULAR THERAPY, 2006, 13 (02) : 250 - 259
  • [9] Systemic administration of L-arginine benefits mdx skeletal muscle function
    Barton, ER
    Morris, L
    Kawana, M
    Bish, LT
    Toursel, T
    [J]. MUSCLE & NERVE, 2005, 32 (06) : 751 - 760
  • [10] Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
    Barton-Davis, ER
    Cordier, L
    Shoturma, DI
    Leland, SE
    Sweeney, HL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (04) : 375 - 381